Prothena Corporation plc (PRTA)
PRTA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1559053/000155905326000008/0001559053-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PRTA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001559053 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Ireland |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $9.7M |
| Net income | -$244.1M |
| Operating income | -$214.6M |
| Net margin | -2520.6% |
| Operating margin | -2216.4% |
| Revenue growth | -92.8% |
| Cash | $307.5M |
| Total assets | $326.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 42.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $271.4M cash; operating cash flow -$7.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 51,349,796 (2026-10-29); 53,829,982 a year earlier; 53,665,349 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $7.3M, sold $136K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $620K | -$16.5M | -$12.0M | $271.4M | No debt tags | $52.7M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $1.0M | -$18.6M | -$25.0M | $288.2M | No debt tags | $54.5M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $51.1M | $32.7M | $28.9M | $329.5M | No debt tags | $57.9M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $21K | -$21.6M | -$23.3M | $307.5M | No debt tags | $9.7M | 10-K 2026-02-27 |
| Q3 2025 2025-09-30 | $2.4M | -$36.5M | -$40.6M | $330.8M | No debt tags | $11.8M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $4.4M | -$125.8M | -$46.3M | $371.4M | No debt tags | $10.3M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $2.8M | -$60.2M | -$53.4M | $417.9M | No debt tags | $137.9M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $2.1M | -$58.0M | -$47.8M | $471.4M | No debt tags | $135.2M | 10-K 2026-02-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-02-27 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-03-27 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.4% |
| 1 month | -2.4% |
| 3 months | -10.1% |
| Year to date | -14.6% |
| 1 year | -19.8% |
| From 52-week high | -29.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PEPG | PepGen Inc. | $4.19 | -3.90% | $395.0M |
| AVTX | Avalo Therapeutics Inc. | $7.37 | -5.03% | $426.2M |
| IRD | Opus Genetics Inc. | $4.04 | +1.51% | $390.5M |
| CTMX | CytomX Therapeutics Inc. | $1.99 | -2.70% | $432.7M |
| BLSM | BlossomHill Therapeutics Inc. | $13.65 | -2.64% | $433.9M |
| RLMD | Relmada Therapeutics Inc. | $3.61 | -14.25% | $385.2M |
| ASMB | Assembly Biosciences Inc. | $21.29 | +0.80% | $436.0M |
| CRMD | CorMedix Inc. | $4.82 | +3.43% | $383.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier